Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
Professor Ritter and his co-workers from the Division of Virology, University Hospital of the RWTH Aachen, created a new recombinant Epstein-Barr Virus (EBV)
which has lost the ability to enter the state of latent persistency after infecting host cells. The mutant virus only causes a self-limited infection and is unable to immortalize B-lymphocytes following Infection. Having lost the oncogenic potential of wild type EBV it fulfils the prerequisite for a live vaccine.
The inventors generated a mutant virus allowing expression of lytic genes, but preventing the expression of EBV encoded genes essential for the establishment of
viral latency. Mutant virus infected B-lymphocytes died after the productive phase….
ONF-MicroMod provides an upgrade for commercially
available laboratory microscopes. Several modules expand a given microscope by a novelty filter based on…
According to the researchers, such a therapy would essentially take advantage of a weakness of the disease: that the majority of growth- and…
Speed is a primary concern in pneumonic plague, which kills in three to four days and potentially could be used in a terrorist attack. The bacterium that…
Surveying vast stellar fields to learn about star interiors and to search for extra-solar planets is the goal of this unique mission, whose scientific…
One of the most interesting examples are those of stars accompanied not only by planets, but also by other stars, making double “Sun” sunsets, and sunrises, no…